FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

174 letters match. Newest first.

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Mseafood Corporation

    Mseafood Corporation lacked required foreign supplier verification for imported cocktail sauce, FDA says.

    Medium
  3. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk
  4. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  5. TCI Co., Ltd BioCosme PABP BRANCH

    FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.

    High risk
  6. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  7. Fresenius Kabi USA LLC

    FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.

    High risk
  8. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.

    High risk
  9. Union Trade Inc.

    FDA warns Union Trade Inc. that it lacked required foreign supplier verification for imported radish, peanuts, mushrooms, and fruit.

    High risk
  10. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  11. K.C. Pharmaceuticals, Inc.

    FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.

    High risk
  12. Safrel Pharmaceuticals LLC

    FDA warned Safrel Pharmaceuticals, an OTC drug labeler in Dayton, New Jersey, that it lacked quality oversight of its suppliers and shipped adulterated drugs.

    High risk
  13. Lico Industries, LLC., d.b.a. American Towelette Company

    FDA warns Lico Industries (American Towelette) that its OTC drug wipes are adulterated due to poor quality oversight, dirty equipment and falsified records.

    High risk
  14. J&B Food Consulting

    J&B Food Consulting lacked a Foreign Supplier Verification Program for imported pet treats; some samples had Salmonella.

    High risk
  15. Excelvision - Fareva

    FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.

    High risk
  16. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  17. Medline Inc

    FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.

    High risk
  18. HealthPartners Neuroscience Center Research and Innovation

    FDA warned HealthPartners Neuroscience Center that its animal studies of an investigational drug violated good laboratory practice rules.

    Medium
  19. IDO Pharm Co., Ltd.

    IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.

    High risk
  20. Ava Inc.

    FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.

    High risk
  21. Nupack Inc.

    FDA warned Nupack Inc. that its dietary supplements were unapproved drugs and made without required manufacturing-practice records.

    High risk
  22. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk
  23. Apollo Care, LLC

    FDA cited Apollo Care for insanitary conditions and quality failures in sterile compounded drugs, including a sterility-assurance recall.

    High risk
  24. Medical Products Laboratories, Inc.

    Medical Products Laboratories was cited for manufacturing failures and selling unapproved prescription skin drugs.

    High risk
  25. Longhorn Vaccines and Diagnostics LLC

    Longhorn Vaccines and Diagnostics sold its PrimeStore MTM sample transport device without required quality controls or clearance for claims beyond its approved uses.

    High risk
  26. Apothecary Pharma, LLC

    FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.

    High risk
  27. Novo Nordisk Inc.

    FDA warns Novo Nordisk over failures to report and investigate serious unexpected adverse drug experiences for drugs including semaglutide.

    High risk
  28. El Rey USA Meats & Seafood Inc.

    FDA found El Rey USA Meats & Seafood lacked required importer verification for shrimp and tilapia.

    High risk
  29. GenoGenix LLC

    FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.

    High risk
  30. A. Nelson & Co. Ltd.

    London homeopathic drug maker A. Nelson & Co. shipped children's products without microbial testing and discarded quality records.

    High risk
  31. AQ USA Inc., d.b.a Ross Healthcare Inc.

    FDA warns AQ USA/Ross Healthcare over current good manufacturing practice violations in drugs, including missing microbial testing and inadequate component and stability controls.

    High risk
  32. MedisourceRx

    MedisourceRx failed to report a serious adverse event and had inadequate procedures, so its compounded drugs lost legal exemptions.

    Medium
  33. Bio-Medical Pharmaceutical Manufacturing Corporation

    Bio-Medical Pharmaceutical Manufacturing, a Houston contract manufacturer, was cited for sterile OTC drug current good manufacturing practice (CGMP) failures and drug listing violations.

    High risk
  34. Central Coast Multispecialty Medical Group, Inc.

    FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.

    High risk
  35. Conceive Fertility Center

    FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.

    High risk
  36. CDL Services, Inc. DBA Technichem

    FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.

    High risk
  37. DeVere Manufacturing Inc.

    FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.

    High risk
  38. PQ Pharmacy, LLC

    FDA warns PQ Pharmacy, a Florida sterile drug compounder, that its products were made under unsafe conditions.

    High risk
  39. Turbare Manufacturing

    FDA warns outsourcing facility Turbare Manufacturing of Conway, Arkansas, for making sterile drugs under insanitary conditions.

    High risk
  40. Wells Pharma of Houston, LLC

    FDA warns Wells Pharma of Houston over sterile compounded drugs made under insanitary conditions.

    High risk
  41. Miers Laboratories, Ltd

    FDA warns Miers Laboratories over manufacturing violations and places import alert on its drugs.

    High risk
  42. Kath Khemicals LLC

    FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.

    High risk
  43. LEVO AG

    FDA says LEVO AG lacked a quality system, adverse-event reporting procedures, and device ID data for standup wheelchairs.

    High risk
  44. Health and Natural Beauty USA Corp.

    FDA warns Health and Natural Beauty USA over CGMP failures and unapproved, misbranded SprinJene OTC toothpastes, including children’s products.

    High risk
  45. Vidaslim Co.

    Vidaslim Co. dietary supplements are adulterated by CGMP failures and misbranded by label violations.

    Medium
  46. Yangzhou Yulou Paper Products Co., Ltd.

    FDA cited Yangzhou Yulou Paper Products for manufacturing violations after records showed its OTC sterile drugs lacked sterility assurance and testing.

    High risk
  47. Somerset Therapeutics Private Limited

    FDA cited Somerset Therapeutics' India plant for CGMP failures tied to a contaminated media fill and aseptic processing risks.

    High risk
  48. DingMoo LLC DBA Dingman’s Dairy

    DingMoo LLC DBA Dingman’s Dairy lacked Foreign Supplier Verification Program records for imported frozen desserts and Pistachio Tartufo tied to a Salmonella outbreak.

    High risk
  49. Mericon Industries, Inc.

    Mericon Industries sold Florical and Meribin supplements with unapproved drug claims for osteoporosis and serious manufacturing and labeling failures.

    High risk
  50. Daewoo Pharmaceutical Co., Ltd.

    FDA warns Daewoo Pharmaceutical over CGMP (manufacturing quality rules) failures at Busan plant; company suspended production.

    High risk